We retrospectively studied all patients referred to three Epilepsy Centres affected by epilepsy occurring in paediatric age and selected 92 patients assuming sustained-release valproate. Our findings underline that VPA, even in extended release form, has good efficacy and safety. In some patients (poor compliance, childhood, adolescents) the single administration improves quality of life.
|Translated title of the contribution||Efficacy and safety of sustained-release valproate in paediatric onset epilepsies: A multi-centre study|
|Number of pages||3|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - Jul 2003|
ASJC Scopus subject areas
- Clinical Neurology